生物医药非临床研究服务

Search documents
上海益诺思生物技术股份有限公司2024年年度报告摘要
Shang Hai Zheng Quan Bao· 2025-04-30 15:27
Core Viewpoint - The company, Yinos, is a leading contract research organization (CRO) in the non-clinical safety evaluation sector, providing comprehensive research services that align with both domestic and international standards, and has recently passed a GLP inspection by the FDA, enhancing its international service capabilities [25][26]. Company Overview - Yinos specializes in non-clinical research services for biopharmaceuticals, being one of the earliest companies in China to obtain GLP certifications from NMPA, OECD, and FDA, thus aligning with international standards [3][4]. - The company has a modern facility of nearly 60,000 square meters and a research team of over 1,000, with locations in Shanghai, Nantong, Shenzhen, Huangshan, and San Francisco [4]. - As of December 31, 2024, Yinos has served over 900 pharmaceutical companies and research institutions, contributing to numerous successful drug development cases [4][18]. Financial Performance - In the reporting period, Yinos achieved a revenue of RMB 1,141.67 million, representing a year-on-year growth of 9.94%, while the net profit attributable to shareholders decreased by 24% to RMB 147.78 million [23]. - The proposed profit distribution plan includes a cash dividend of RMB 3.2 per 10 shares, totaling RMB 45.11 million, which accounts for 30.53% of the net profit for the year [1]. Industry Context - The global CRO market is projected to grow at a compound annual growth rate (CAGR) of 9.0% from 2023 to 2026, with the market size expected to exceed USD 147.7 billion by 2030 [11]. - In China, the CRO service market is estimated to reach RMB 848.2 billion in 2023, with a projected CAGR of 9.9% from 2023 to 2026 [12]. - The industry is supported by government policies aimed at enhancing drug research and development capabilities, which is expected to drive long-term growth in the CRO sector [13][14]. Technological Advancements - Yinos is investing in artificial intelligence (AI) applications in non-clinical research, aiming to enhance efficiency and reduce costs in drug development processes [19]. - The company is also exploring organoid technology for drug screening and toxicity testing, which is gaining traction in the pharmaceutical research field [19][20]. Strategic Positioning - Yinos has established strong partnerships with leading pharmaceutical companies, positioning itself as a strategic partner in the innovative drug development process [18][21]. - The company is expanding its international presence, having established a subsidiary in the United States to enhance its global market share [22].
上海益诺思生物技术股份有限公司第三届监事会第十次会议决议公告
Shang Hai Zheng Quan Bao· 2025-04-18 23:27
登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:688710 证券简称:益诺思 公告编号:2025-008 上海益诺思生物技术股份有限公司 第三届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海益诺思生物技术股份有限公司(以下简称"公司")第三届监事会第十次会议于2025年4月18日在公 司会议室以现场结合通讯的方式召开,本次会议应出席监事3人,实际出席会议监事3人。会议由公司监 事会主席高莉女士主持。 此次会议的通知、召集、召开、表决程序符合《中华人民共和国公司法》等法律、法规、规范性文件及 《公司章程》的规定,会议决议合法有效。 二、监事会会议审议情况 1、审议通过了《关于2025年度日常关联交易预计的议案》。 经审核,监事会认为:关于2025年度日常关联交易预计事项,属于正常的商业交易行为,符合公司正常 生产经营活动需要,关联交易的预计发生价格遵循市场化原则,合理、公允,不会对公司独立性产生不 利影响,不存在向关联方输送利益的情况,不会损害公司、股东特 ...
上海益诺思生物技术股份有限公司_招股说明书(上会稿)
2023-09-06 09:08
本次股票发行后拟在科创板市场上市,科创板公司具有研发投入大、经营 风险高、业绩不稳定、退市风险高等特点,投资者面临较大的市场风险。投资 者应充分了解科创板的投资风险及本公司所披露的风险因素,审慎作出投资决 定。 科创板投资风险提示 上海益诺思生物技术股份有限公司 Shanghai InnoStar Bio-tech Co., Ltd. (中国(上海)自由贸易试验区郭守敬路 199 号 106 室) 首次公开发行股票并在科创板上市 招股说明书 (上会稿) 声明:本公司的发行申请尚需经上海证券交易所和中国证监会履行相应程 保荐机构(主承销商) (上海市广东路 689 号) 序。本招股说明书不具有据以发行股票的法律效力,仅供预先披露之用。 投资者应当以正式公告的招股说明书作为投资决定的依据。 上海益诺思生物技术股份有限公司 招股说明书(上会稿) 重要声明 | 发行股票类型 | 人民币普通股(A 股) | | --- | --- | | 发行股数 | 本次拟公开发行股票不超过 万股,不低于发行后总股 3,524.4904 | | | 本的 25%。 | | | 本次发行全部为新股发行,原股东不公开发售股份。 | | ...